Share General Information
Afatinib dimaleate, the dimaleate salt form of afanitib, is an orally available antineoplastic agent. It is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test. In the past, standard treatment with a platinum-based chemotherapy doublet regimen was considered standard first-line therapy for all patients with NSCLC. However, emerging evidence has identified subpopulations in which targeted therapy is more effective, leading to the development of mutation-specific drugs.
About the API
-
Japan DMF
-
Korea DMF
-
US DMF
The information detailed herein, including that with regard to active pharmaceutical ingredients , their use in treatments and possible mechanism(s) of action, was all obtained from public sources.
For more information on our services and products – including product suitability, intended uses and current availability – please contact Teva api Customer Service. CAS Registry Number is a Registered Trademark of the American Chemical Society. This webpage and any reference to the above product is to be read within the meaning and terms of the Legal Notes.
